CPP (Cancer Prevention Pharmaceuticals) EBIT per Share : $-0.92 (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals EBIT per Share?

Cancer Prevention Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2016 was $-0.39. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.92.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's EBIT per Share or its related term are showing as below:

CPP's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 8.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cancer Prevention Pharmaceuticals's EBIT for the three months ended in Mar. 2016 was $-2.13 Mil.

Cancer Prevention Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals EBIT per Share Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

EBIT per Share

-1.13

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
EBIT per Share	Get a 7-Day Free Trial			-	-	-	-0.53	-0.39

Cancer Prevention Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cancer Prevention Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2015 is calculated as

	EBIT per Share		(A: Dec. 2015 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.923	/	3.468
=	-1.13

Cancer Prevention Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2016 is calculated as

	EBIT per Share		(Q: Mar. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.128	/	5.495
=	-0.39

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.92

Cancer Prevention Pharmaceuticals (AMEX:CPP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cancer Prevention Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.